StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $4.25 price target on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $4.06.

OncoCyte Trading Down 4.8 %

Shares of NASDAQ:OCX opened at $3.00 on Friday. The company has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $2.94. OncoCyte has a twelve month low of $2.08 and a twelve month high of $4.34.

OncoCyte (NASDAQ:OCX) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.